ProSavin® for the treatment of Parkinson’s disease (PD)
 

Oxford BioMedica Announces Interim Data from Highest (5x) Dose Cohort in ProSavin Phase I/II Study in Parkinson's Disease

04 Aug 2011

-- Positive interim review of fourth patient cohort by Data Monitoring Committee --

Oxford, UK | August 4, 2011 | Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, today announces positive interim data from the on-going Phase I/II trial of ProSavin® for the treatment of Parkinson’s disease (PD). The first three patients in the current six-patient cohort were treated with a 5x dose of ProSavin®, the scaled equivalent to the maximum dose in pre-clinical studies, and have reached their three-month assessment.

Highlights of fourth patient cohort at three months (n=3, 5x dose)

Favourable safety profile with no serious adverse events related to ProSavin® or its method of administration;
Data Monitoring Committee (DMC) supports current planning for randomised studies;
Highest average motor function¹ improvement of 29% at this time point, with a maximum of 49% improvement in one patient; and
Reduction in average daily dose of L-DOPA "equivalent" therapy.